Blackrock’s Sending THIS Crypto Higher on Purpose

It's a groundbreaking opportunity that could be poised for extraordinary gains. The catalyst behind this surge is a massive new blockchain development…

Lota Zoth Biography and Net Worth

Director of Inovio Pharmaceuticals

Lota S. Zoth CPA serves as Independent Director of the Company. Ms. Zoth qualifies to serve on our Board as a result of her years of experience in senior financial roles in a variety of commercial-stage companies over a 35-year career. She currently serves as the chairman of the board of directors of the publicly held biopharmaceutical company Zymeworks, Inc. and also serves on the board of directors of the publicly held biopharmaceutical company Lumos Pharma, Inc. (formerly NewLink Genetics Corporation). Within the last five years, she also served on the boards of directors of the public companies Spark Therapeutics, Inc. and Orexigen Therapeutics, Inc. (which was granted relief under Chapter 11 of the U.S. Bankruptcy Code in 2019). Prior to her board service, she served in senior financial roles in a variety of commercial-stage companies, including serving as MedImmune Inc.’s corporate controller from 2002 to 2004 and its chief financial officer from 2004 until its acquisition by AstraZeneca in 2007. Prior to joining MedImmune in 2002, Ms. Zoth served in financial executive roles at PSINet Inc., Sodexho Marriott Services, Inc., Marriott International and PepsiCo, Inc. Ms. Zoth also served as an auditor at Ernst & Young, LLP and is a Certified Public Accountant. Ms. Zoth holds a B.B.A. in accounting from Texas Tech University.

What is Lota S. Zoth's net worth?: The estimated net worth of Lota S. Zoth is at least $811.74 as of May 17th, 2021. Ms. Zoth owns 166 shares of Inovio Pharmaceuticals stock worth more than $812 as of November 14th. This net worth evaluation does not reflect any other investments that Ms. Zoth may own. Learn More about Lota S. Zoth's net worth.
How do I contact Lota S. Zoth?: The corporate mailing address for Ms. Zoth and other Inovio Pharmaceuticals executives is 660 W. GERMANTOWN PIKE SUITE 110., PLYMOUTH MEETING PA, 19462. Inovio Pharmaceuticals can also be reached via phone at (267) 440-4200 and via email at [email protected]. Learn More on Lota S. Zoth's contact information.
Has Lota S. Zoth been buying or selling shares of Inovio Pharmaceuticals?: Lota S. Zoth has not been actively trading shares of Inovio Pharmaceuticals in the last ninety days. Most recently, Lota S. Zoth sold 14 shares of the business's stock in a transaction on Monday, May 17th. The shares were sold at an average price of $953.28, for a transaction totalling $13,345.92. Following the completion of the sale, the director now directly owns 166 shares of the company's stock, valued at $158,244.48. Learn More on Lota S. Zoth's trading history.
Who are Inovio Pharmaceuticals' active insiders?: Inovio Pharmaceuticals' insider roster includes Simon Benito (Director), Laurent Humeau (Insider), Peter Kies (CFO), Jong Kim (CEO), Jacqueline Shea (COO), David Weiner (Director), and Lota Zoth (Director). Learn More on Inovio Pharmaceuticals' active insiders.

Lota S. Zoth Insider Trading History at Inovio Pharmaceuticals

Transaction Date	Buy/Sell	Number of Shares	Average Share Price	Total Transaction	Shares Held After Transaction	Details
5/17/2021	Sell	14	$953.28	$13,345.92	166

Lota S. Zoth Buying and Selling Activity at Inovio Pharmaceuticals

Inovio Pharmaceuticals Company Overview

Inovio Pharmaceuticals, Inc., a biotechnology company, focuses on the discovery, development, and commercialization of DNA medicines to treat and protect people from diseases associated with human papillomavirus (HPV), cancer, and infectious diseases. Its DNA medicines platform uses precisely designed SynCon that identify and optimize the DNA sequence of the target antigen, as well as CELLECTRA smart devices technology that facilitates delivery of the DNA plasmids. Its products in pipeline include VGX-3100 for the treatment of HPV-related cervical high-grade dysplasia; INO-3107 for HPV-related recurrent respiratory papillomatosis and is under Phase 1/2 trial; INO-3112 for the treatment of HPV-related Oropharyngeal Squamous Cell Carcinoma and is under Phase 2 trial; INO-5401 for the treatment of glioblastoma multiforme and is under Phase 2 trial; INO-4201 for Ebola Virus Disease and is under Phase 1b trial; INO-4800 for COVID-19 and is under Phase 3 trial; and INO-6160 for the treatment of human immunodeficiency virus and is under Phase 1 trial. Its partners and collaborators include Advaccine Biopharmaceuticals Suzhou Co, ApolloBio Corporation, AstraZeneca, The Bill & Melinda Gates Foundation, Coalition for Epidemic Preparedness Innovations, Defense Advanced Research Projects Agency, The U.S. Department of Defense, HIV Vaccines Trial Network, International Vaccine Institute, Kaneka Eurogentec, National Cancer Institute, National Institutes of Health, National Institute of Allergy and Infectious Diseases, the Parker Institute for Cancer Immunotherapy, Plumbline Life Sciences, Regeneron Pharmaceuticals, Richter-Helm BioLogics, Thermo Fisher Scientific, the University of Pennsylvania, the Walter Reed Army Institute of Research, and The Wistar Institute. The company was incorporated in 1983 and is headquartered in Plymouth Meeting, Pennsylvania.

Today's Range

Now: $4.89

$4.86

$5.02

50 Day Range

MA: $5.83

$4.95

$6.82

2 Week Range

Now: $4.89

$4.20

$14.75

Volume

171,773 shs

Average Volume

399,353 shs

Market Capitalization

$126.94 million

P/E Ratio

N/A

Dividend Yield

N/A

Beta

0.83